ArticleScience advances2021
Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status.
Abstract read
In one paragraph
Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Desmoplasia and therapeutic resistance in pancreatic ductal adenocarcinoma.Cancer letters · 2026Review
- Article
- Inhibition of Focal Adhesion Restricts Chemoresistance in Pancreatic Cancer by Targeting SLC7A11 Mediated Ferroptosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling.Nature communications · 2026Article
- Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion-Defined Rhabdomyosarcoma.Molecular cancer therapeutics · 2025Article
- Modeling tumor dynamics and predicting response to therapies in a murine pancreatic cancer model.NPJ systems biology and applications · 2025Article
- Dynamic regulation of integrin β1 phosphorylation supports invasion of breast cancer cells.Nature cell biology · 2025Article
- Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis.Science advances · 2025Article
- Focal adhesion kinase signaling - tumor vulnerabilities and clinical opportunities.Journal of cell science · 2024Review
- Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response.Science advances · 2024Article
- Injectable hybrid hydrogels enable enhanced combination chemotherapy and roused anti-tumor immunity in the synergistic treatment of pancreatic ductal adenocarcinoma.Journal of nanobiotechnology · 2024Article
- Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid Metabolism.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Evidence and therapeutic implications of biomechanically regulated immunosurveillance in cancer and other diseases.Nature nanotechnology · 2024Review
- Defined extracellular matrix compositions support stiffness-insensitive cell spreading and adhesion signaling.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- High frequency of alternative splicing variants of the oncogene Focal Adhesion Kinase in neuroendocrine tumors of the pancreas and breast.Frontiers of medicine · 2023Article
- Reshaping the Pancreatic Cancer Microenvironment at Different Stages with Chemotherapy.Cancers · 2023Review
- Functional biomaterials for biomimetic 3D in vitro tumor microenvironment modeling.In vitro models · 2023Review
- Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma.Science advances · 2023Article
- Article
- Therapeutic Strategies to Overcome Fibrotic Barriers to Nanomedicine in the Pancreatic Tumor Microenvironment.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors.
Kendelle J MurphyGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0002-3234-3812
Daniel A ReedGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0002-3736-7725
Claire VenninGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.
James R W ConwayGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0003-3787-277X
Max NobisGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0002-1861-1390
Julia X YinGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0002-7706-5895
Cecilia R ChambersGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0002-4979-9349
Brooke A PereiraGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0003-3513-1214
Victoria LeeGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0002-0701-8321
Elysse C FilipeGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0003-1956-0852
Michael TrpceskiGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.
Shona RitchieGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0001-9234-0632
Morghan C LucasGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0001-7654-9137
Sean C WarrenGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0002-5253-7147
Joanna N SkhinasGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.
Astrid MagenauGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.
Xanthe L MetcalfGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0001-9599-9280
Janett StoehrGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0002-4198-3520
Gretel MajorGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0002-4275-4199
Ashleigh ParkinGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.
Romain BidanelGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.
Ruth J LyonsGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.
Anaiis ZaratzianGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.
Michael TayaoGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0001-5224-0784
Andrew Da SilvaGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.
Lea AbdulkhalekGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.
Australian Pancreatic Genome Initiative (APGI)
Australian Pancreatic Cancer Matrix Atlas (APMA)
Anthony J GillGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0002-9447-1967
Amber L JohnsGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.
Andrew V BiankinInstitute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-0362-5597
Jaswinder SamraDepartment of Surgery, Royal North Shore Hospital, Sydney, NSW 2065, Australia.
Sean M GrimmondUniversity of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, 305 Grattan Street, Melbourne, VIC 3000, Australia.ORCID 0000-0002-8102-7998
Angela ChouGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0001-9212-6927
Jacky G GoetzINSERM UMR, Tumour Biomechanics, Strasbourg, France.ORCID 0000-0003-2842-8116
Michael S SamuelCentre for Cancer Biology, SA Pathology and University of South Australia, SA, Australia.ORCID 0000-0001-7880-6379
J Guy LyonsDermatology, Sydney Medical School, University of Sydney, Camperdown, NSW, Australia.ORCID 0000-0002-4835-4663
Andrew BurgessANZAC Research Institute, Sydney, NSW 2139, Australia.ORCID 0000-0003-4536-9226
C Elizabeth CaldonGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0003-1392-3472
Lisa G HorvathGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.
Roger J DalyCancer Program and Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC 3800, Australia.ORCID 0000-0002-5739-8027
Nikolaj GadegaardJames Watt School of Engineering, University of Glasgow, Glasgow, UK.ORCID 0000-0002-3396-846X
Yingxiao WangDepartment of Bioengineering and Institute of Engineering in Medicine, University of California, San Diego, La Jolla, CA, USA.ORCID 0000-0003-0265-326X
Owen J SansomInstitute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0001-9540-3010
Jennifer P MortonInstitute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0001-5766-9141
Thomas R CoxGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0001-9294-1745
Marina PajicGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0002-3871-3829
David HerrmannGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0002-9514-7501
Paul TimpsonGarvan Institute of Medical Research and The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia.ORCID 0000-0002-5514-7080
Funding
Acoustothermogenetics for Cell EngineeringR35GM140929 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI WANG, YINGXIAO · 2021 to 2025
$2.9MNew tools for quantitative non-invasive recording of biochemical signalsR01CA279813 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jennifer Prescher, Nathan Christopher Shaner · 2024 to 2026
$2.0MUltrasound-controlled remote activation of CAR T cells for localized tumor immunotherapyR01EB029122 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI WANG, YINGXIAO · 2020 to 2023
$1.7MCancer Research UK 21139Cancer Research UK 29996NCI NIH HHS R01 CA279813NIBIB NIH HHS R01 EB029122NIGMS NIH HHS R35 GM140929
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic, chemoresistant malignancy and is characterized by a dense, desmoplastic stroma that modulates PDAC progression. Here, we visualized transient manipulation of focal adhesion kinase (FAK), which integrates bidirectional cell-environment signaling, using intravital fluorescence lifetime imaging microscopy of the FAK-based Förster resonance energy transfer biosensor in mouse and patient-derived PDAC models. Parallel real-time quantification of the FUCCI cell cycle reporter guided us to improve PDAC response to standard-of-care chemotherapy at primary and secondary sites. Critically, micropatterned pillar plates and stiffness-tunable matrices were used to pinpoint the contribution of environmental cues to chemosensitization, while fluid flow–induced shear stress assessment, patient-derived matrices, and personalized in vivo models allowed us to deconstruct how FAK inhibition can reduce PDAC spread. Last, stratification of PDAC patient samples via Merlin status revealed a patient subset with poor prognosis that are likely to respond to FAK priming before chemotherapy.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.